Estrella Immunopharma
ESLA
Market cap $42M

1.16 USD

+0.06

5.45%

At close Dec 20, 4:00 PM EST

1 day

5.45%

5 days

12.62%

1 month

26.02%

3 months

14.85%

6 months

31.82%

Year to date

0.87%

1 year

-7.20%

5 years

-66.57%

10 years

-66.57%

About: Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,809 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

80% more capital invested

Capital invested by funds: $129K [Q2] → $232K (+$103K) [Q3]

43% more funds holding

Funds holding: 7 [Q2] → 10 (+3) [Q3]

0.21% more ownership

Funds ownership: 0.34% [Q2] → 0.55% (+0.21%) [Q3]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ESLA.

See Analyst Rankings

Financial journalist opinion

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient enrolled in its STARLIGHT-1 Phase I/II clinical trial has achieved a complete response (CR) one month after receiving an infusion of EB103 CD19- Redirected ARTEMIS® T Cells. In a clinical trial, a c.

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) ("Estrella", “Estrella Immunopharma”, or the "Company"), a clinical stage biopharmaceutical company focused on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancers and autoimmune diseases, today announced the appointment of Hong Zhang as Chairperson and a member of its Board of Directors. This appointment comes shortly after the Company dosed the first patient in its Phase I/II clinica.

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances

The International Monetary Fund believes that most of the impact from tighter money policies has already affected the U.S. economy, with the rest expected this year. Despite worries about a recession, the U.S. has shown resilience and strong growth since interest rates started going up in March 2022.

Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances

See News Rankings

Charts implemented using Lightweight Charts™